IPO News | Legend Biotech (LEGN.US) Reportedly Considering Second Listing Outside US, Hong Kong Among Potential Locations

Stock News

09/08

According to reports, Legend Biotech (LEGN.US) is considering a second listing outside the United States due to strong investor interest in pharmaceutical companies. Sources familiar with the matter indicate that potential listing locations include Hong Kong, Singapore, and London. A second listing in Hong Kong, in particular, could help boost Legend Biotech's valuation. The report notes that Legend Biotech is still in the consideration phase and may decide not to proceed with a second listing. Representatives from Legend Biotech declined to comment.

Legend Biotech was founded in 2014 and went public on the US NASDAQ in 2020. The company specializes in CAR-T cell immunotherapy for cancer treatment, with its flagship product ciltacabtagene autoleucel already approved by the US FDA for market.

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/1161475716"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1161475716\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1161475716?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-09-08 10:12","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1161475716","market":"nz","top_or_hot":-1,"title":"IPO News | Legend Biotech (LEGN.US) Reportedly Considering Second Listing Outside US, Hong Kong Among Potential Locations","media":"Stock News","content":"<p>According to reports, Legend Biotech (LEGN.US) is considering a second listing outside the United States due to strong investor interest in pharmaceutical companies. Sources familiar with the matter indicate that potential listing locations include Hong Kong, Singapore, and London. A second listing in Hong Kong, in particular, could help boost Legend Biotech's valuation. The report notes that Legend Biotech is still in the consideration phase and may decide not to proceed with a second listing. Representatives from Legend Biotech declined to comment.</p>\n<p>Legend Biotech was founded in 2014 and went public on the US NASDAQ in 2020. The company specializes in CAR-T cell immunotherapy for cancer treatment, with its flagship product ciltacabtagene autoleucel already approved by the US FDA for market.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>IPO News | Legend Biotech (LEGN.US) Reportedly Considering Second Listing Outside US, Hong Kong Among Potential Locations</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nIPO News | Legend Biotech (LEGN.US) Reportedly Considering Second Listing Outside US, Hong Kong Among Potential Locations\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time smaller\">2025-09-08 10:12</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<p>According to reports, Legend Biotech (LEGN.US) is considering a second listing outside the United States due to strong investor interest in pharmaceutical companies. Sources familiar with the matter indicate that potential listing locations include Hong Kong, Singapore, and London. A second listing in Hong Kong, in particular, could help boost Legend Biotech's valuation. The report notes that Legend Biotech is still in the consideration phase and may decide not to proceed with a second listing. Representatives from Legend Biotech declined to comment.</p>\n<p>Legend Biotech was founded in 2014 and went public on the US NASDAQ in 2020. The company specializes in CAR-T cell immunotherapy for cancer treatment, with its flagship product ciltacabtagene autoleucel already approved by the US FDA for market.</p>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"","article_id":"1161475716","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1161475716","pubTimestamp":1757297537,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"According to reports, Legend Biotech (LEGN.US) is considering a second listing outside the United States due to strong investor interest in pharmaceutical companies. Sources familiar with the matter...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","BK4585":"ETF&股票定投概念","LEGN":"传奇生物","BK4588":"碎股","BK4505":"高瓴资本持仓"},"translate_title":"IPO快讯|传奇生物(LEGN.US)据报道考虑在美国、香港以外的潜在地点进行第二次上市","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"LEGN":1},"content_text":"According to reports, Legend Biotech (LEGN.US) is considering a second listing outside the United States due to strong investor interest in pharmaceutical companies. Sources familiar with the matter indicate that potential listing locations include Hong Kong, Singapore, and London. A second listing in Hong Kong, in particular, could help boost Legend Biotech's valuation. The report notes that Legend Biotech is still in the consideration phase and may decide not to proceed with a second listing. Representatives from Legend Biotech declined to comment.\nLegend Biotech was founded in 2014 and went public on the US NASDAQ in 2020. The company specializes in CAR-T cell immunotherapy for cancer treatment, with its flagship product ciltacabtagene autoleucel already approved by the US FDA for market.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}